AP2014007915A0 - Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-YL]amino}phenyl)suloximide for treating specific tumours - Google Patents

Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-YL]amino}phenyl)suloximide for treating specific tumours

Info

Publication number
AP2014007915A0
AP2014007915A0 AP2014007915A AP2014007915A AP2014007915A0 AP 2014007915 A0 AP2014007915 A0 AP 2014007915A0 AP 2014007915 A AP2014007915 A AP 2014007915A AP 2014007915 A AP2014007915 A AP 2014007915A AP 2014007915 A0 AP2014007915 A0 AP 2014007915A0
Authority
AP
ARIPO
Prior art keywords
suloximide
methylpropyl
pyrimidin
cyclopropyl
oxy
Prior art date
Application number
AP2014007915A
Other languages
English (en)
Inventor
Martin Kornacker
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47891732&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014007915(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of AP2014007915A0 publication Critical patent/AP2014007915A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2014007915A 2012-03-21 2013-03-18 Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-YL]amino}phenyl)suloximide for treating specific tumours AP2014007915A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012204506 2012-03-21
PCT/EP2013/055561 WO2013139734A1 (de) 2012-03-21 2013-03-18 Verwendung von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung spezifischer tumore

Publications (1)

Publication Number Publication Date
AP2014007915A0 true AP2014007915A0 (en) 2014-09-30

Family

ID=47891732

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007915A AP2014007915A0 (en) 2012-03-21 2013-03-18 Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-YL]amino}phenyl)suloximide for treating specific tumours

Country Status (20)

Country Link
US (1) US20150051232A1 (xx)
EP (1) EP2827871A1 (xx)
JP (1) JP2015510910A (xx)
KR (1) KR20140135215A (xx)
CN (1) CN104220075A (xx)
AP (1) AP2014007915A0 (xx)
AU (1) AU2013234451A1 (xx)
CA (1) CA2867746A1 (xx)
CL (1) CL2014002472A1 (xx)
EA (1) EA201491732A1 (xx)
HK (1) HK1204294A1 (xx)
MA (1) MA35943B1 (xx)
MX (1) MX2014011240A (xx)
PH (1) PH12014502075A1 (xx)
SA (1) SA113340398B1 (xx)
SG (1) SG11201405386SA (xx)
TN (1) TN2014000391A1 (xx)
TW (1) TW201338779A (xx)
WO (1) WO2013139734A1 (xx)
ZA (1) ZA201406986B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015071231A1 (de) * 2013-11-14 2015-05-21 Bayer Pharma Aktiengesellschaft Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren
ES2951596T3 (es) 2014-06-13 2023-10-23 Bach Biosciences Llc Agentes terapéuticos activados por FAP y usos relacionados con los mismos

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1307271A (en) 1970-06-25 1973-02-14 Shell Int Research Sulphoximine derivatives and their use in herbicidal compositions
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ATE336484T1 (de) 1998-08-29 2006-09-15 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
JP4771576B2 (ja) * 2000-06-12 2011-09-14 譲治 稲澤 Ｇａｓｃ１遺伝子
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
EP1392662B1 (de) 2001-05-29 2009-01-07 Bayer Schering Pharma Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
EP1483260A1 (de) 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
WO2004041267A1 (en) * 2002-11-06 2004-05-21 Cyclacel Limited Combination comprising a cdk inhibitor and cisplatin
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179991A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
CN102223885B (zh) * 2008-11-24 2013-04-03 内尔维阿诺医学科学有限公司 用于治疗间皮瘤的cdk抑制剂
EP2424843B1 (en) * 2009-04-30 2014-03-26 Novartis AG Imidazole derivatives and their use as modulators of cyclin dependent kinases
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren

Also Published As

Publication number Publication date
ZA201406986B (en) 2016-08-31
AU2013234451A1 (en) 2014-09-25
TN2014000391A1 (en) 2015-12-21
CN104220075A (zh) 2014-12-17
MA35943B1 (fr) 2014-12-01
EA201491732A1 (ru) 2015-08-31
MX2014011240A (es) 2014-10-15
SA113340398B1 (ar) 2016-04-04
CA2867746A1 (en) 2013-09-26
JP2015510910A (ja) 2015-04-13
TW201338779A (zh) 2013-10-01
KR20140135215A (ko) 2014-11-25
CL2014002472A1 (es) 2014-12-12
WO2013139734A1 (de) 2013-09-26
SG11201405386SA (en) 2014-11-27
PH12014502075A1 (en) 2014-12-10
US20150051232A1 (en) 2015-02-19
EP2827871A1 (de) 2015-01-28
HK1204294A1 (en) 2015-11-13

Similar Documents

Publication Publication Date Title
IL242278A0 (en) Compounds 4)-n-fluoro-2-methoxy-5-nitrophenyl)pyrimidine-2-converted amine and their salts
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
SG10201704992SA (en) Lsr antibodies, and uses thereof for treatment of cancer
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
HK1206338A1 (en) Pyrimidine compounds for the treatment of cancer
EP2725903A4 (en) 3-ALKOXY, THIOALKYL AND AMINO-4-AMINO-6- (SUBSTITUTED) PICOLINATES AND THEIR USE AS HERBICIDES
EP2925752A4 (en) PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
EP2807551A4 (en) ROAD CHARACTERISTICS OF NOTES
EP2731429A4 (en) COMPOUNDS, METHODS OF PREPARATION AND METHODS OF USE
IL231444A0 (en) Aniline derivatives, their preparation and medical application
UA108494C2 (xx) Застосування (rs)-s-цикропропіл-s-(4-{$4-{$(1r,2r)-2-гідрокси-1-метилпропіл]окси}-5-(трифторметил)піримідин-2-іл]аміно}феніл)сульфоксіміду для лікування пухлин
EP2757092A4 (en) SUBSTITUTED CYANANILIN COMPOUNDS, METHOD OF MANUFACTURING THEREOF AND USE THEREOF
EP2903979A4 (en) Novel compounds, their preparation and use
EP2700429A4 (en) DRUG SOLUTION APPLICATOR
ZA201406986B (en) Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours
HK1191942A1 (zh) 新型六氫環戊二烯並吡咯酮，六氫吡咯並吡咯酮，八氫吡咯並吡啶酮和八氫吡啶酮化合物
SG11201501289TA (en) Preparation for preventing or treating type i diabetes
IL240977A0 (en) Use of (sr)-s-cyclopropyl-s-(4-{[4-{[(r2,r1)-2-hydroxy-1-methylpropyl]-oxy}-5-(trifluoromethyl)pyrimidin-2-yl] Amino}phenyl)sulfoxide for the treatment of certain tumors
IL232339A0 (en) 32rf10c antibodies, and their uses for cancer treatment
IL232340A0 (en) lsr antibodies, and their uses for cancer treatment
GB201118482D0 (en) Treating tumours
GB201116328D0 (en) Treatment for tumours